OncoMatch/Esophageal Cancer/FGFR2
Esophageal CancerFGFR2 Clinical Trials
2 recruiting trials·Updated daily from ClinicalTrials.gov
FGFR2 amplification occurs in approximately 5–10% of esophageal and GEJ adenocarcinomas and represents an emerging therapeutic target in this disease. Bemarituzumab, targeting FGFR2b, is under evaluation in FGFR2b-overexpressing GEJ/gastric/esophageal adenocarcinoma following the positive FIGHT trial signal. Trials investigate FGFR inhibitors and FGFR2-directed agents in combination with chemotherapy or immunotherapy for FGFR2-altered esophageal adenocarcinoma.
Top recruiting
Top recruiting FGFR2 Esophageal Cancer trials
Ranked by phase and US site count. See all 2 trials matched to your profile →
Other Esophageal Cancer biomarkers
Browse other molecular targets with active Esophageal Cancer trials.